Last update :
11/08/2022
References   References 4617  
Type : Manufacturer

Research teams :
Authors :
Title : Isatuximab - SARCLISA 20mg/mL concentrate for solution for infusion - Summary of Product Characteristics - updated 16 August 2021
Reference : Sanofi Genzyme 2021

Level of Evidence : 
Manufacturer's stability data
Physical stability : 
Chemical stability : 
Other methods : 
Comments : 

List of drugs
InjectionIsatuximab Anticancer drug
Stability in solutions Polyvinyl chloride NaCl 0,9% or Glucose 5% ? mg/ml 15-25°C Not specified
8 Hour
Stability in solutions Polyvinyl chloride NaCl 0,9% or Glucose 5% ? mg/ml 2-8°C Not specified
48 Hour
Stability in solutions Polypropylene NaCl 0,9% or Glucose 5% ? mg/ml 15-25°C Not specified
8 Hour
Stability in solutions Polypropylene NaCl 0,9% or Glucose 5% ? mg/ml 2-8°C Not specified
48 Hour
Stability in solutions Polyethylene NaCl 0,9% or Glucose 5% ? mg/ml 15-25°C Not specified
8 Hour
Stability in solutions Polyethylene NaCl 0,9% or Glucose 5% ? mg/ml 2-8°C Not specified
48 Hour
Stability in solutions Polyolefine NaCl 0,9% or Glucose 5% ? mg/ml 15-25°C Not specified
8 Hour
Stability in solutions Polyolefine NaCl 0,9% or Glucose 5% ? mg/ml 2-8°C Not specified
48 Hour
Stability in solutions Ethylene vinyl acetate NaCl 0,9% or Glucose 5% ? mg/ml 15-25°C Not specified
8 Hour
Stability in solutions Ethylene vinyl acetate NaCl 0,9% or Glucose 5% ? mg/ml 2-8°C Not specified
48 Hour

  Mentions Légales